中新网广州12月14日电 (记者 杨薇)香港卡施健医药公司14日与中国科学院广州生物医药与健康研究院联合签署了合作协议，双方科研人员将携手开发新型抗糖尿病药物。

A guangzhou, 14 dec (Reporter YangWei)Hong Kong card ShiJian pharmaceutical company 14 and the Chinese academy of sciences guangzhou biological medicine and health research institute jointly signed a cooperation agreement,The researchers will, hand in hand, development of new diabetes drug resistance.

　　这也是该院首次与外资企业签约合作。

This is the first hospital and the foreign capital enterprise contract cooperation.

　　在签约仪式上，双方签订了《“1.1类新型抗糖尿病候选药物DK3”专利海外开发权独家授权许可协议》，签约金额达一千万美元。接下来，双方科研人员将在药物优化、药物作用机制的研究上进行深入合作。

At a signing ceremony,The both sides signed a["1.1 class new anti-diabetic drug candidates DK3"Patent rights overseas sole license agreement],Signing amounted to us $ten million.The next,The scientific research personnel will be in drug optimization/Drug action mechanism research on the further cooperation.

　　据该合作项目负责人、香港卡施健医药公司首席执行官李昊财透露，该公司将通过与具有世界先进制药与生物技术开发经验的国际团队合作，协助中国科学院广州生物医药与健康研究院在全球范围内进一步开发该新药，争取在五年内让新药物上市，以期能早日为糖尿病患者带来福音。

According to the cooperation project principal/Hong Kong card ShiJian pharmaceutical company CEO LiHao wealth has revealed,The company will be through with the world's advanced pharmaceutical and biotechnology development experience of international team,To assist the Chinese academy of sciences guangzhou biological medicine and health research institute in the global scope further development of the new drug,In the five years to make the new drugs on the market,In order to early for patients with diabetes can bring the Gospel.

　　中国科学院广州生物医药与健康研究院结构生物学研究室主任刘劲松表示，这种新型抗糖尿病药物是该院自主设计研发的1.1类新药候选物，适应症为Ⅱ型糖尿病。新研发的药物具有全新的化学结构和明确的作用机制，成药性高。

The Chinese academy of sciences guangzhou biological medicine and health research institute structure biology research director LiuJinSong said,This new type of diabetes drug resistance is the hospital independent design and development of new drug candidates 1.1 class content,Indications for Ⅱ diabetes.New research and development of new drugs have the chemical structure and mechanism of action of clear,Into a high.

　　目前该项目已基本完成临床前研究，其药学、体内外药效学、急性毒性、药动学等实验研究与临床上广泛应用的同类抗糖尿病药物直接对比优势明显，并已申请中国、美国、日本、欧洲、澳大利亚、加拿大及香港等主要国家和地区专利，目前正组织申报临床试验。

The project has been completed before the clinical research,The pharmacy/In vivo pharmacodynamics/Acute toxicity/Pharmacokinetics and experimental research and clinical widely used similar diabetes drug resistance direct comparison of the obvious advantages,And has applied for China/The United States/Japan/The European/Australia/Canada and Hong Kong and other major countries and regions patent,Is currently organization declaration clinical trials.

　　现今，糖尿病已经成为全球性的流行病，严重威胁人类的健康。目前在全球范围内，估计有3.71亿糖尿病患者，其发病数已经达到流行病的规模，而中国有超过9千万的糖尿病患者，为世界之最。糖尿病的治疗已经成为社会公共健康的一个主要负担。

now,Diabetes has become a global epidemic,A serious threat to human health.At present in the global scope,An estimated 371 million diabetic patients,The onset of number has reached the scale of the epidemic,And China has more than 90 million patients with diabetes,As the world's most.The treatment of diabetes has become a social public health a major burden.

　　当天，中国科学院广州生物医药与健康研究院还与广东三家医药公司签署合作协议，将在开发治疗老年痴呆、白血病、肺癌、丙型肝炎、鼻咽癌等疾病上开发新药。(完)

the,The Chinese academy of sciences institute of guangzhou biological medicine and health with guangdong three medical signed a cooperation agreement,In the development of the treatment of senile dementia/leukemia/Lung cancer/Hepatitis c/The new development of nasopharyngeal carcinoma and other diseases.(finish)